Adherence by African American men to prostate cancer education and early detection

Cancer

Volumn 86, Issue 1, 1999, Pages 88-104

  Myers, Ronald E ^a   Chodak, Gerald W ^b   Wolf, Thomas A ^a   Burgh, Desiree Y ^a   McGrory, Gene T ^a   Marcus, Sue M ^a   Diehl, Julie A ^a   Williams, Melissa ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b WEISS MEMORIAL HOSPITAL   (United States)

Author keywords

African Americans; Early detection; Education; Prostate cancer; Screening

Indexed keywords

ADULT; AGED; ARTICLE; BEHAVIOR MODIFICATION; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; PATIENT EDUCATION; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AFRICAN AMERICANS; AGED; CULTURAL CHARACTERISTICS; HUMANS; INTERVENTION STUDIES; MALE; MASS SCREENING; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PROSTATIC NEOPLASMS; RANDOM ALLOCATION; SOCIAL SUPPORT;

EID: 0033168904     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990701)86:1<88::AID-CNCR14>3.0.CO;2-D     Document Type: Article

References (46)

1. American Cancer Society. Cancer facts & figures. Atlanta: American Cancer Society, 1998:20-4.
2. Fincham SM, Hill GB, Hanson J, Wijaysinghe C. Epidemiology of prostatic cancer: a case-control study. Prostate 1990; 17:189-206.
3. Steinberg GD, Carter BS, Beaty TH. Family history and the risk of prostate cancer. Prostate 1990;17:337-47.
4. Ries LAG, Kosary CL, Hankey BF, Miller BA. SEER cancer statistics review, 1973-1994. NIH Publication No. 97-2789. Bethesda, MD: National Cancer Institute, 1997.
5. Ndubuisi SC, Kofie W, Andoh JY, Schwartz EM. Black-white differences in the stage at presentation of prostate cancer in the District of Columbia. Urology 1995;46:771-7.
6. Roach M. Is race an independent prognostic factor for survival from prostate cancer? J Natl Med Assoc. In press.
7. Roach M, Lu J, Pilepich M, Asbell SO, Mohuidden M, Terry R, Grignon D. Long-term survival in 1500 men treated for prostate cancer with radiotherapy alone (XRT). Based on Radiation Therapy Oncology Group (RTOG) protocols 7706, 7506, 8531, and 8610. J Urol 1998;159:219.
8. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995;273:289-94.
9. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270:948-54.
10. Bales GT, Gerber GS. Screening for the early detection of carcinoma of the prostate. Principles Pract Oncol 1995;9:1-9.
11. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-6.
12. Mettlin C, Jones G, Averette H, Gusberg SB, Murphy GP. Defining and updating the American Cancer Society guidelines for the cancer-related checkup: prostate and endometrial cancers. CA Cancer J Clin 1993;43:42-6.
13. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA 1994;272:773-80.
14. Walsh PC, Brooks JD. The Swedish prostate cancer paradox. JAMA 1997;277:497-8.
15. Gohagan JK, Prorok PC, Kramer BS, Cornett JE. Prostate cancer screening in the prostate, lung, colorectal and ovarian cancer screening trial of the National Cancer Institute. J Urol 994;152:1905-9.
16. Prorok P. The National Cancer Institute Multi-Screening Trial. Can J Oncol 1994;4(Suppl):98-9.
17. Schroder FH. The European Screening Study for Prostate Cancer. Can J Oncol 1994;4(Suppl):102-5.
18. Labrie F, Dupont A, Candas B, Cusan L, Gomez JL, Diamond P, et al. Decrease of prostate cancer death by screening: first data from the Quebec prospective and randomized study. Program/Proceedings, American Society of Clinical Oncology, 34th Annual Meeting, May 16-19, 1998.
19. Wasson JH, Cushman CC, Bruskewitz RC, Uttenberg B, Mulley AG, Wennberg JE. The Prostate Disease Patient Outcome Research Team. Arch Fam Med 1993;2:487-93.
20. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcome in men treated for localized prostate cancer. JAAM 1995;273:129-35.
21. U.S. Preventive Services Taskforce. Guide to clinical preventive services. 2nd Edition. Baltimore: Williams and Wilkins, 1996:119-34.
22. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1991 update. 3. Secondary prevention of prostate cancer. Can Med Assoc J 1991;145:413-28.
23. Coley CM, Barry MJ, Mulley AG. Screening for prostate cancer. Clinical guideline. Part III. Ann Intern Med 1997;126: 480-4.
24. Vernon SW, Myers RE, Tilley BC Development and validation of an instrument to measure factors related to colorectal cancer screening adherence. Cancer Epidemiol Biomarkers Prev 1997;6:825-32.
25. Antonovsky A. The sense of coherence as a determinant of health. In: D Matarazzo, SM Weiss, JA Herd, NE Miller, SM Weiss, editors. Behavioral health: a handbook of health enhancement and disease prevention. New York: John Wiley & Sons Inc., 1984:114-29.
26. Strecher VJ, Rosenstock IM. The health belief model. In: Glanz K, Lewis FM, Rimer B, editors. Health behavior and health education: theory, research and practice. 2nd edition. San Francisco: Jossey-Bass Publishers, 1997:41-59.
27. Ajzen I, Fishbein M. Understanding, attitudes and predicting social behavior. Englewood Cliffs, NJ: Prentice-Hall, 1980.
28. Bandura A. Social foundations of thought and action: a social cognitive theory. Englewood Cliffs, NJ: Prentice-Hall, 1986.
29. Myers RE, Wolf T, McKee L, McGrory G, Burgh DY, Nelson G, et al. Factors associated with intention to have annual prostate cancer screening among African American men in Philadelphia. Cancer 1996;78:471-9.
30. Myers R, Wolf T, Balshem A, Ross E, Chodak GW. Receptivity of African American men to prostate cancer screening. Urology 1994;43:480-7.
31. Myers RE, Vernon SW, Tilley BC, Liu M, Watts BG. Intention to screen for colorectal cancer among white male employees. Prev Med 1998;27:279-87.
32. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med 1997;337:295-300.
33. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. Br J Urol 1997;79:235-46.
34. Pilepich M, Caplan R, Byhardt R, Lawton C, Gallagher M, Mesic J, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of RTOG Protocol 85-31. J Clin Oncol 1997;15:1013-21.
35. Flood AB, Wennberg JE, Nease RF, Fowler FJ, Ding J, Hynes LM. The importance of patient preference in the decision to screen for prostate cancer. J Gen Intern Med 1996;11:342-9.
36. Wolf AMD, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med 1996;156:1333-6.
37. Kasper JF, Mulley AG Jr., Wennberg JE. Developing shared decision-making programs to improve the quality of health care. Qual Rev Bull 1992;18:183-90.
38. Deber R. Shared decision making in the real world [editorial]. J Gen Intern Med 1996;11:377-8.
39. Ubel PA. Informed consent: from bodily invasion to the seemingly mundane. Arch Intern Med 1996;156:1262-3.
40. Wolf AMD, Philbrick JT, Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent. Am J Med 1997;103:308-14.
41. Onel E, Hamond C, Wasson JH, Berlin BB, Ely MG, Laudone VP, et al. Assessment of the feasibility and impact of shared decision making in prostate cancer. Urology 1998; 51:63-6.
42. Krongrad A, Kim CO Jr., Burke MA, Granville LJ. Not all patients pursue prostate biopsy after abnormal prostate specific antigen results. Urol Oncol 1996;2:325-39.
43. Schapira MM, McAuliffe TL, Nattinger AB. Treatment of localized prostate cancer in African-American compared to Caucasian men. Med Care 1995;33:1079-88.
44. Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B. Geographic, age and racial variation in the treatment of local/ regional carcinoma of the prostate. J Clin Oncol 1995; 13:93-100.
45. Demark-Wahnefried W., Schildkraut JM, Iselin CE, Conlisk E, Kavee A, Aldrich TE, et al. Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer 1998;53: 320-30.
46. Smith GE, DeHaven MJ, Grundig JP, Wilson GR. African-American men and prostate cancer: assessing knowledge levels in the community. J Natl Med Assoc 1997; 89:387-91.